55276-43-2

Basic information

• Product Name: 1-METHANESULFONYL-PIPERAZINE
• Synonyms: 1-METHANESULFONYL-PIPERAZINE;1-N-METHANESULFONYLPIPERAZINE;1-(METHYLSULFONYL)PIPERAZINE;1-METHYLSULPHONYLPIPERAZINE;AKOS B003961;CHEMBRDG-BB 3003961;IFLAB-BB F2124-0764;ART-CHEM-BB B022241
• CAS NO: 55276-43-2
• Molecular Formula: C₅H₁₂N₂O₂S
• Molecular Weight: 164.23
• Product Categories: Amines and Anilines;Heterocycles;piperazines
• Mol File: 55276-43-2.mol

Chemical Properties

• Melting Point: 99 °C
• Boiling Point: 280.6 °C at 760 mmHg
• Flash Point: 123.5 °C
• Appearance: /Solid
• Density: 1.29 g/cm³
• Vapor Pressure: 0.00374mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.78±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 1-METHANESULFONYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHANESULFONYL-PIPERAZINE(55276-43-2)
• EPA Substance Registry System: 1-METHANESULFONYL-PIPERAZINE(55276-43-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-36/37/39-24/25-23
• HazardClass: IRRITANT
• Hazardous Substances Data: 55276-43-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Chemical Research:
1-METHANESULFONYL-PIPERAZINE is used as an intermediate for the development and synthesis of various pharmaceutical compounds and chemicals. Its versatile chemical structure allows it to be a key component in the creation of new drugs and chemical products, contributing to advancements in these fields.

InChI:InChI=1/C5H12N2O2S/c1-10(8,9)7-4-2-6-3-5-7/h6H,2-5H2,1H3

Upstream product

• 349403-24-3 4-methanesulfonyl-piperazine-1-carboxylic acid ethyl ester 
• 110-85-0 piperazine 
• 124-63-0 methanesulfonyl chloride 
• 164331-38-8 tert-butyl 4-(methylsulfonyl)piperazine-1-carboxylate 
• 14172-55-5 1-(phenylsulphonyl)piperazine 
• 118546-61-5 N-benzyl-N'-methanesulphonylpiperazine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 90671-47-9 1-[(4-Isopropyl-phenyl)-(3-methyl-isothiazol-5-yl)-methyl]-4-methanesulfonyl-piperazine 
• 423747-61-9 1-(methanesulfonyl)-4-(4-nitrobenzyl)piperazine 
• 850171-04-9 2-bromo-4-(4-methanesulfonylpiperazin-1-ylmethyl)aniline 
• 423743-43-5 1-(4-bromobenzyl)-4-methanesulfonylpiperazine 
• 850170-96-6 N-benzhydrylidene-N'-[4-(4-methanesulfonylpiperazin-1-ylmethyl)phenyl]hydrazine 
• 850171-46-9 trans-3-{2-[5-(4-methanesulfonylpiperazin-1-ylmethyl)-2-nitrophenyl]vinyl}quinoline 
• 863969-66-8 2-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-2-nitro-phenyl]-1-quinolin-3-yl-ethanol 

Relevant articles and documents

Synthesis and biological evaluation of ethacrynic acid derivatives bearing sulfonamides as potent anti-cancer agents

A series of ethacrynic acid (2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid) (EA, Edecrin) containing sulfonamides linked via three types of linkers namely 1,2-ethylenediamine, piperazine and 4-aminopiperidine was synthesized and subsequently evaluated in vitro against HL60 and HCT116 cancer cell lines. All the EA analogs, excluding 6a and 6c, showed anti-proliferative activity with IC50s in the micromolar range (less than 4 uM). Three derivatives 6b, 7b and 7e were selected for their interesting dual activity on HL60 cell line in order to be further evaluated against a panel of cancer cell lines (HCT116, A549, MCF7, PC3, U87-MG and SKOV3) as well as on MRC5 as a normal cell line. These compounds displayed IC50 values in nanomolar range against A549, MCF7, PC3 and HCT116 cell lines, deducing the discovery that piperazine or 4-aminopiperidine is the linker's best choice to develop EA analogs with highly potent anti-proliferative activities own up to 24 nM. Besides, in terms of selectivity, those linkers are more suitable offering safety ratios of up to 63.8.

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα

PI3K signal pathway plays a vital role in cellular functions and becomes an attractive approach for cancer therapy. Herein, a new series of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives bearing sulfonylpiperazine based on the PI3K inhibitors and our previous research. They were screened for their PI3K inhibitory activities and anticancer effects in vitro. Biological studies indicated that compound 7m revealed the remarkable antiproliferative activity (IC50 ranging from 0.03 to 0.09 μM) against four cancer cell lines (A549, Huh7, HL60 and HCT-116). Besides, compound 7m displayed a certain selective for PI3Kα (IC50 = 0.009 μM) over PI3Kβ, γ and δ, and meanwhile, it can remarkable decreased the expression level of p-Akt (Ser473) and p-S6K. In addition, compound 7m could not only induce HCT-116 cell arrest at G1 phase in a dose-dependent manner, but also induce cell apoptosis via upregulation of Bax and cleaved-caspase 3/9, and downregulation of Bcl-2. Besides, compound 7m can remarkably inhibit the growth of tumor in vivo. The above results suggested that compound 7m could be considered as a promising PI3Kα inhibitor.

Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase

Human tissue transglutaminase (hTG2) is a multifunctional enzyme. It is primarily known for its calcium-dependent transamidation activity that leads to formation of an isopeptide bond between glutamine and lysine residues found on the surface of proteins, but it is also a GTP binding protein. Overexpression and unregulated hTG2 activity have been associated with numerous human diseases, including cancer stem cell survival and metastatic phenotype. Herein, we present a series of targeted covalent inhibitors (TCIs) based on our previously reported Cbz-Lys scaffold. From this structure-activity relationship (SAR) study, novel irreversible inhibitors were identified that block the transamidation activity of hTG2 and allosterically abolish its GTP binding ability with a high degree of selectivity and efficiency (kinact/KI > 105 M-1 min-1). One optimized inhibitor (VA4) was also shown to inhibit epidermal cancer stem cell invasion with an EC50 of 3.9 μM, representing a significant improvement over our previously reported "hit" NC9.

QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF

Quinoline compounds are disclosed that have a formula represented by the following: and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.

7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS

The present invention relates to novel series of substituted 7-(morpholinyl)-2-(N-piperazinyl)-methyl thieno [2, 3-c] pyridines of the following structure of formula I. Where in R1, R2, R3 and R4 are defined.

Phosphoinositides 3-serinekinase inhibitor compd. antialopecic agent and combinations, and method of use

Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

CARBODITHIOATES WITH SPERMICIDAL ACTIVITY AND PROCESS FOR PREPARATION THEREOF

The present invention relates to the synthesis and biological evaluation of compound of formula I as spermicidal agents, and its pharmaceutically acceptable acid salt thereof. The invention provides bis(4- substituted-1-piperazinylthiocarbonyl) disulfide (when n = 0) and alkane-1,n-diylbis(4-substituted piperazine-1-carbodithioate) (when n = 0, 1, 2 or 3) as shown in figure 1 of the accompanying drawing. These compounds are found to be useful for spermicidal activity.

SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof and a pharmaceutical composition for treating metabolism-related disorder containing the same. Specifically, the present invention relates to a compound of the formula 1, which can activate GPR119 to treat metabolism-related disorders, including diabetes and related diseases, diabetes-related microvascular complications, diabetes-related macrovascular complications, cardiovascular abnormalities, metabolic syndrome and its constituent diseases, and obesity.